Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 3/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927501 | 0.99 | FFAR4 (0.41) | FFAR4ALDH1A1LMNAMAPK1LRRK2 | |
| SCHEMBL5926503 | 0.99 | FFAR4 (0.41) | FFAR4ALDH1A1LMNAMAPK1LRRK2 | |
| SCHEMBL3995848 | 0.98 | FFAR4 (0.43) | FFAR4ALDH1A1LMNAMAPK1LRRK2 | |
| SCHEMBL5926774 | 0.92 | MMP12 (0.41) | FFAR4ALDH1A1LMNAMAPK1LRRK2 | |
| SCHEMBL5927222 | 0.92 | CTSA (0.44) | ALDH1A1LMNAMAPK1LRRK2KMT2A | |
| SCHEMBL5926489 | 0.91 | CTSA (0.43) | ALDH1A1LMNAMAPK1LRRK2KMT2A | |
| SCHEMBL3995217 | 0.90 | PTPN11 (0.46) | FFAR4ALDH1A1LMNAMAPK1NPSR1 | |
| SCHEMBL5927462 | 0.90 | LRRK2 (0.44) | FFAR4ALDH1A1LMNAMAPK1LRRK2 | |
| SCHEMBL5926898 | 0.90 | FFAR4 (0.46) | FFAR4ALDH1A1LMNAMAPK1POLB | |
| SCHEMBL5927061 | 0.90 | LRRK2 (0.50) | FFAR4ALDH1A1LMNAMAPK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | FFAR4 1026/4885ALDH1A1 2142/4885LMNA 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.